文献速递特殊人群用药药物不良反应与药物警戒

欧盟上市后研究注册中风险最小化措施有效性评估研究的设计、过程与结局指标

Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
PubMed 文献 · Br J Clin Pharmacol · 2018-12-27

该定性综述检索截至2018年6月30日EU PAS注册库中范围定义为「有效性评估」的研究,筛选出35项评估风险最小化措施(RMM)有效性的研究,其中29项符合综述条件。所有研究均评估过程指标,仅5项同时评估结局指标,但无研究采用前后对照设计;仅4项研究设定了阈值(均为过程指标)。

要点

  • 多数RMM有效性评估研究仅关注过程指标,结局指标应用不足。
  • 仅4项研究设定了阈值,且均为过程指标,缺乏结局阈值。
  • 无研究采用前后对照设计比较RMM实施前后不良结局频率。

核心结论

  • 更严格遵循现有推荐可提高RMM有效性评估设计的稳健性,有助于达到既定终点并促进研究标准化。

研究设计与样本

  • 定性综述,检索EU PAS注册库至2018年6月30日,筛选范围定义为「有效性评估」的研究。
  • 从360项注册研究中识别35项评估RMM有效性的研究,29项符合综述条件。

主要发现

  • 所有研究均评估过程指标,5项同时评估结局指标(采用双证据方法)。
  • 5项采用双证据方法的研究均未使用前后对照设计比较RMM实施前后不良结局频率。
  • 行为和知识是最常评估的过程指标;结局指标包括不良反应发生、妊娠、超说明书使用和用药错误。
  • 仅4项研究设定了阈值,均为过程指标。

临床怎么用

  • 临床药学智能体在解读RMM有效性研究时,应关注过程指标与结局指标的平衡及阈值设定情况。
  • 评估RMM研究设计时,需注意是否采用前后对照设计以比较不良结局频率变化。

局限性

  • 检索截止2018年6月30日,未涵盖此后注册的研究。
  • 仅基于EU PAS注册库,可能遗漏其他来源的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risk minimization measures (RMMs) represent an essential tool for preventing the occurrence of safety-related outcomes. The evaluation of RMMs effectiveness is essential to prove their success and ensure protection of public health. The aim of this qualitative review was to assess the design, process and outcome indicators used for attesting successful implementation of RMMs. We searched the EU Post-Authorization Studies Register up to 30 June 2018 for studies having the scope defined as 'effectiveness evaluation'. Study titles and objectives were screened to select the ones evaluating the effectiveness of RMMs. We described and assessed the extent to which these studies aligned with Good Pharmacovigilance Practices guidelines recommendations. Out of 360 registered studies, we identified 35 studies on evaluation of RMMs effectiveness, 29 being eligible for review. Twenty-six studies evaluated additional RMMs, employed in case routine interventions are considered insufficient. All studies assessed process indicators, five also assessing outcome indicators, thus using a dual-evidence approach as recommended by the guidelines. However, none of the latter used a pre-post design, comparing the frequency of the adverse outcome before and after the implementation of RMMs. Behaviour and knowledge were the most often assessed process indicators. Outcome indicators included occurrence of adverse reactions, pregnancy, off-label use and medication errors. Only four studies had an established threshold, all for process indicators. Stricter adherence to existing recommendations would allow for a more robust design for reaching established endpoints for RMM effectiveness evaluation. It would also infer harmonization, facilitate review and further more detailed guidance on conducting these studies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Farcas A, Huruba M, Mogosan C, et al. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register. Br J Clin Pharmacol. 2018. PMID: 30497102. doi:10.1111/bcp.13824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。